WO2018169027A1 - Phytochemical absorption promoter - Google Patents

Abstract

Disclosed is a hardly water-soluble phytochemical absorption promoter capable of significantly increasing the speed and/or amount of the intake of a phytochemical into the body, in particular, the transition thereof into the blood. A lactobacillus product containing a polysaccharide can significantly increase the speed and/or amount of the intake of a phytochemical into the body, in particular, the transition thereof into the blood. Therefore, the phytochemical absorption promoter according to the present invention comprises the lactobacillus product as an active ingredient. Moreover, the phytochemical absorption promoter is useful as a food additive. By adding the phytochemical absorption promoter to a food, a beverage or a food or beverage composition, an effect of promoting phytochemical absorption can be imparted thereto.

Description

Phytochemical absorption accelerator

The present invention relates to a phytochemical absorption promoter having an action of promoting absorption of a poorly water-soluble phytochemical into the body.

Phytochemicals generally mean plant-derived compounds that are not required for normal physical function maintenance but have a positive effect on health. For example, polyphenol isoflavone is abundant in soybeans and exhibits the functions of menopausal disorder improvement and osteoporosis prevention. Quercetin is abundant in onions and exhibits functions of improving blood flow and reducing body fat. Β-carotene, a terpenoid, is abundant in carrots and pumpkins, and functions to maintain visual function, mucous membranes and skin of the body, and immune function, and lycopene is abundant in tomatoes, reducing blood cholesterol and blood pressure. Indicates.

It is known that many phytochemicals are decomposed and lost by processing / cooking, and further have poorly water-soluble components, so that they are poorly transferred to the living body. As a method for promoting the absorption of a poorly water-soluble phytochemical, a method for improving solubility and dispersibility by making an emulsion formulation, a method for reducing the particle diameter, and a method for making it amorphous are often used.

Furthermore, as a technique for promoting absorption of poorly water-soluble phytochemicals, for example, JP-A-2016-216440 (Patent Document 1) discloses resveratrol, hesperetin, lacanca (as a catechin absorption promoter) Siraitia grosvenorii extract, jujuba var.inermis extract, citrus aurantiifolia extract, lemon (Citrus limon) extract, pineapple (Ananas comosus) extract, apigenin, glucose, difructose dianhydride III At least one selected from the group consisting of sucralose, aspartame or a salt thereof, erythritol, inositol, citric acid or a salt thereof, phytic acid or a salt thereof, and gallic acid or a salt thereof is disclosed.

JP-A-2016-93143 (Patent Document 2) discloses the absorption of polyphenols such as catechins and the like into plasma by adding polyphenols such as catechins having low bioavailability to fats and carbohydrates of a specific formulation. There is a disclosure that it is possible to improve the accumulation of.

In addition, JP-T-2016-506181 (Patent Document 3) discloses a catechin bioavailability enhancer containing cyclodextrin as an active ingredient.

However, these documents do not disclose that a product of lactic acid bacteria containing a polysaccharide as an active ingredient has an action of promoting phytochemical absorption.

On the other hand, combinations of lactic acid bacteria and phytochemicals are disclosed in, for example, Japanese Patent Application Laid-Open No. 8-322464 (Patent Document 4). This publication discloses fermented milk in which about 0.1 to 2,000 ppm of catechins and tocopherols are contained in yogurt containing lactic acid bacteria and bifidobacteria, respectively. It is said that the survivability is improved. Japanese Patent Publication No. 2015-527076 (Patent Document 5) describes a method for producing a dairy-based nutritional composition having a rich texture and can contain phytochemicals. However, none of these patent documents disclose that a product of lactic acid bacteria has an action of promoting absorption of phytochemicals.

JP 2016-216440 A JP 2016-93143 A Special table 2016-506181 JP-A-8-322464 Special table 2015-527076 gazette

The present inventors have now found that lactic acid bacteria products containing polysaccharides significantly increase the uptake of poorly water-soluble phytochemicals into the body, particularly the rate and / or amount of transfer into the blood. It was. The present invention is based on such knowledge.

Accordingly, an object of the present invention is to provide a phytochemical absorption promoter having an action of promoting absorption of a poorly water-soluble phytochemical into the body.

Another object of the present invention is to provide a food additive comprising the poorly water-soluble phytochemical absorption accelerator, and a food or drink or a food or drink composition to which they are added.

The poorly water-soluble phytochemical absorption enhancer according to the present invention comprises a lactic acid bacteria product containing a polysaccharide as an active ingredient.

Moreover, the food additive, food / beverage product or food / beverage product composition according to the present invention comprises the poorly water-soluble phytochemical absorption accelerator according to the present invention.

The present invention also relates to a method for promoting the uptake of a poorly water-soluble phytochemical into the human or animal body, which comprises administering or ingesting the lactic acid bacteria product containing the polysaccharide to the human or animal. .

The present invention also relates to the use of a lactic acid bacteria product containing a polysaccharide for promoting the incorporation of a poorly water-soluble phytochemical into the human or animal body.

The present invention also relates to the use of a lactic acid bacterium product containing a polysaccharide for the production of the poorly water-soluble phytochemical absorption promoter.

It is a graph showing the change of the quercetin conjugate density | concentration in a serum when quercetin alone or a quercetin and yogurt is administered simultaneously to a rat. It is a graph showing the change of the isorhamnetin conjugate density | concentration in serum when a rat is administered quercetin alone or quercetin and yogurt simultaneously. It is a graph showing the change of the quercetin conjugate density | concentration in serum when a quercetin and skim milk powder alone or a quercetin and a yoghurt is administered simultaneously to a rat. It is a graph showing the change of the serum isorhamnetin conjugate density | concentration when quercetin and nonfat dry milk only or quercetin and yogurt are administered simultaneously to a rat. It is a graph showing the change of the quercetin conjugate density | concentration in a serum when a quercetin alone or a quercetin and a polysaccharide concentrate are administered simultaneously to a rat. It is a graph showing the change of the serum isorhamnetin conjugate density | concentration when a quercetin alone or a quercetin and a polysaccharide concentrate are administered simultaneously to a rat. It is a graph showing the change of the concentration of genistein conjugate in serum when genistein alone or genistein and yogurt are administered simultaneously to rats. It is a graph showing the change of epicatechin conjugate concentration in serum when epicatechin alone or epicatechin and yogurt are administered simultaneously to rats. It is a graph showing the change of the beta-carotene density | concentration in a serum when administering only beta-carotene or beta-carotene and yoghurt simultaneously to a rat. It is a graph showing the change of the beta-carotene density | concentration in serum when a beta-carotene and skim milk powder alone, or beta-carotene and yogurt are administered simultaneously to a rat. It is a graph showing the change of the concentration of β-carotene in serum when β-carotene alone or β-carotene and polysaccharide concentrate are simultaneously administered to rats. It is a graph showing the change of the quercetin conjugate density | concentration in serum when (alpha) glucosyl rutin alone or (alpha) glucosyl rutin and yogurt are administered simultaneously to a rat. It is a graph showing the change of the isoramnetin conjugate density | concentration in serum when (alpha) glucosyl rutin alone or (alpha) glucosyl rutin and yogurt are administered simultaneously to a rat. It is a graph showing the change of the serum luteolin conjugate concentration when luteolin alone or luteolin and yogurt were administered simultaneously to rats. It is a graph showing the change of serum naringenin conjugate concentration when naringenin alone or naringenin and yogurt are administered simultaneously to rats. It is a graph showing the change of the lycopene density | concentration in serum when a lycopene only or a lycopene and a yoghurt is administered simultaneously to a rat. It is a graph showing the change of the epicatechin conjugate density | concentration in a blood serum when the cocoa bean origin extract alone or the cocoa bean origin extract and yogurt are administered simultaneously to a rat.

Phytochemical In the present invention, “phytochemical” is a natural chemical substance present in plants, a modified product thereof, and a composition containing them, and is not essential for maintaining normal body functions, It means a compound or composition that is or will be ingested as having a positive effect on maintenance and improvement. Therefore, in the present invention, the phytochemical refers to a plant-derived composition in the form of a plant-derived composition containing such a compound as a main component in addition to a plant-derived pure or compound having a certain degree of purity, for example, a fraction. Shall mean.

According to a preferred embodiment of the present invention, phytochemical means, for example, polyphenols, organic sulfur compounds, terpenoids and the like.

In the present invention, preferred examples of polyphenols include flavonoids, shigetones, tetraterpenes, and specific examples thereof include flavones (for example, apigenin, luteolin, etc.), isoflavones (for example, apigenin, luteolin, etc.). , Genistein, daidzein, etc.), flavonols (eg, quercetin, myricetin, kaempferol, etc.), flavanones (eg, hesperetin, naringenin, etc.), flavan-3-ols (eg, catechin, epicatechin, etc.), anthocyanins (eg, cyanidin) , Delphinidin, etc.). Moreover, curcumin is mentioned as a shigeton.

Also, preferred examples of the organic sulfur compound include isocyanates (for example, sulforaphane), cysteine sulfoxides (for example, methylcysteine sulfoxide), and sulfines (for example, allicin).

Further, examples of terpenoids include tetraterpenes, and specific examples thereof include carotenoids (for example, β-carotene, lycopene, lutein, astaxanthin, etc.).

Furthermore, in the present invention, the phytochemical includes those analogs, and preferred examples thereof include glucoside (genistin) and conjugate (glucuronic acid conjugate, sulfate conjugate) for genistin, and quercetin. Methylated (isoramnetin), glycoside (rutin, quercetin glucoside), conjugate (glucuronic acid conjugate, sulfate conjugate) for kaempferol, glycoside (hesperidin) and conjugate (glucuronic acid conjugate, Sulfate conjugates). Furthermore, for epicatechin and catechin, isomers (catechin), polymers (procyanidin B1, procyanidin B2, procyanidin B5, procyanidin C1, etc.), conjugates (glucuronic acid conjugates, sulfate conjugates) and gallic esters (epicatechin gallate) , Epigallocatechin gallate). Examples of hesperetin include glycosides (hesperidin) and conjugates (glucuronic acid conjugates, sulfate conjugates), and naringenin includes glycosides (naringenin) and conjugates (glucuronic acid conjugates, sulfate conjugates). For β-carotene, isomers (α-carotene, γ-carotene) and metabolites (retinol palmitate, apo-10-carotenal, retinol) and metabolites (apo-10-lycopenal) for lycopene are included.

Furthermore, in the present invention, phytochemicals include plant-derived extracts and concentrates. Preferred examples include genistein extracts and concentrates derived from soybeans, red beans, peas and empty beans, quercetin extracts and concentrates derived from onions and apples, and kaempferol derived from tea and broccoli. Extracts and concentrates, cacao beans for epicatechin and catechin, extracts and concentrates derived from tea, hesperetin extracts and concentrates derived from Wenzhou oranges, extracts and concentrates derived from grapefruit and orange for naringenin, Extracts and concentrates from egoma, perilla, spring chrysanthemum and peppers for luteolin, ginseng and spinach extracts and concentrates for β-carotene, tomato-derived extracts and concentrates for lycopene, cacao beans for epicatechin The extract and concentrate of origin are mentioned.

In the present invention, the phytochemical is sparingly water-soluble. According to a preferred embodiment of the present invention, the poorly water-soluble phytochemical is one having a water solubility of 88% or less, more preferably 50% or less, more preferably 20% or less, and most preferably 1. % Phytochemical. Here, the “dissolution rate” in the present invention is an index representing the ease of dissolution of the compound in water, and the concentration of the supernatant after centrifugation after dissolving the compound in pure water by shaking. The value obtained by dividing (w / v) by the concentration (w / v) before dissolution by shaking is shown as a percentage (%). The concentration can be measured using a spectrophotometer. In the present invention, a solution prepared by adding 33.3 mg of the phytochemical compound to 10 mL of pure water is preferably used for measuring the “dissolution rate”. In the case of a more poorly water-soluble phytochemical, the “dissolution rate” may be measured using a solution prepared by adding 3.3 mg to 10 mL of pure water. The temperature condition for measuring the “dissolution rate” is 21 ± 2 ° C. In addition, the poor water solubility of phytochemicals is determined by the “concentration (w / v) of supernatant obtained by dissolving the compound by shaking in pure water and then centrifuging” obtained in the measurement of the “dissolution rate”. In this case, the dissolution rate in water of 88% or less corresponds to 293 mg / 100 g or less. In addition, it is thought that it is not essential that the phytochemical used as the object of absorption promotion in this invention exists in the aspect melt | dissolved in water. That is, it is considered that the effect of promoting absorption according to the present invention can be obtained even for phytochemicals taken in a solid state or suspended in water.

Absorption accelerating agent In the present invention, the absorption promotion of phytochemical refers to the rate of phytochemical uptake into the body, particularly the transfer to the blood, compared to a control ingested without lactic acid bacteria products containing polysaccharides. And / or means significantly increasing the amount of migration. Specifically, after administration, this means either or both of producing a high blood concentration compared to the control or a large blood concentration-time curve area (AUC) compared to the control. To do. Thereby, the effect of phytochemical intake can be obtained in a smaller amount or in a shorter time, and the raw material cost can be reduced. Moreover, by adding the phytochemical absorption promoter according to the present invention to foods and drinks and food and drink compositions, it is possible to increase the added value of food and drinks and increase the commercial value.

In the lactic acid bacteria producing organisms present invention containing polysaccharide, a "lactic acid bacteria producing organism" containing polysaccharide, in addition to the lactic acid bacteria fermentation product, lactic acid bacteria culture, the lactic acid bacteria metabolites like, to containing polysaccharides by fermentation of lactic acid bacteria Is broadly meant.

In the present specification, the “polysaccharide” is a sugar chain polymer composed of sugars such as galactose, glucose, rhamnose, mannose, N-acetylglucosamine. In addition to neutral polysaccharides, the polysaccharides may include acidic polysaccharides to which phosphate groups are bonded. The molecular weight is usually in the range of 5000 to 500,000.

In this specification, the term “lactic acid bacteria” is a general term for microorganisms that assimilate glucose and produce lactic acid with a yield of sugar of 50% or more. It has characteristics such as no sex, no sporulation ability, and catalase negative. Lactic acid bacteria have been eaten all over the world through fermented milk since ancient times, and can be said to be extremely safe microorganisms. To date, lactic acid bacteria have been genus Lactococcus, Lactobacillus, Leuconostoc, Pediococcus, Streptococcus, Wissella, Tetrageno The genus is classified into 11 genera such as Tetragenococcus genus, Oenococcus genus, Enterococcus genus, Vagococcus genus and Carnobacterium genus. In the embodiment of the present invention, all these lactic acid bacteria can be used.

According to a preferred embodiment of the present invention, it is particularly preferred to use Lactobacillus delbrueckii subsp. Bulgaricus in combination with Streptococcus thermophilus among the above.

According to a further preferred embodiment of the present invention,
Lactobacillus delbruecki subspecies bulgaricus
Using Lactobacillus delbruecki subspecies bulgaricus OLL1247 or Lactobacillus delbrucky subspecies bulgaricus OLL1224,
As Streptococcus thermophilus,
Streptococcus thermophilus OLS3078 or Streptococcus thermophilus OLS3290 is used.

Here, Lactobacillus delbruecki subspecies bulgaricus OLLG1247 is dated March 6, 2014 (consignment date), and is the Patent Evaluation Microorganism Depositary Center for Product Evaluation Technology (Kazusa, Kisarazu, Chiba, Japan). It is deposited internationally under the Budapest Treaty under the accession number NITE BP-01814.

Furthermore, Lactobacillus delbruecki subspecies bulgaricus OLL 1224 bacteria was issued on July 2, 2009 (contract date) as the accession number NITE BP-778 to the Patent Microorganism Depositary of the National Institute of Technology and Evaluation of the National Institute of Technology and Evaluation. Deposited internationally under the Budapest Treaty.

Also, Streptococcus thermophilus OLS3078 was deposited internationally under the Budapest Treaty as a deposit number NITE BP-01697, on August 23, 2013 (date of trust), to the National Institute of Technology and Evaluation of the National Institute of Technology and Evaluation, with the accession number NITE BP-01697. ing.

Furthermore, Streptococcus thermophilus OLS3290 was internationally deposited under the Budapest Treaty on January 19, 2004 (consignment date), under the accession number FERM BP-19638, to the National Institute of Technology and Technology Patent Microorganisms Deposited Microorganisms. Yes.

In the present specification, the “fermented product of lactic acid bacteria” means a culture obtained by fermentation with lactic acid bacteria, a composition comprising the same, and a composition after treatment. Therefore, the fermented lactic acid bacteria include a fermented lactic acid bacterium and a processed product thereof, for example, a culture filtrate or culture supernatant obtained by sterilizing a culture (fermented lactic acid bacterium) by filtration, centrifugation, membrane separation, or the like. Liquid, culture filtrate / culture supernatant, lactic acid bacteria fermentation product, and the like concentrated by an evaporator or the like, pasted product, diluted product, or dried product (for example, frozen, heated, reduced pressure, etc.). The treatment can be carried out by combining one or more of the above treatment steps such as sterilization treatment such as filtration, centrifugation, membrane separation, precipitation, concentration, pasting, dilution, drying and the like. In addition, examples of the culture medium include nonfat dry milk medium and MRS medium to which yeast extract is added.

According to a preferred embodiment of the present invention, the lactic acid bacteria product is particularly preferably a milk fermentation product, a milk culture, or a milk metabolite of lactic acid bacteria. Examples of the fermented milk product, the milk culture product, and the milk metabolite include fermented milk (yogurt). In the present invention, fermented milk (yogurt) can be preferably used as its supernatant. The fermented milk may contain a thickener and a gelling agent such as pectin, guar gum, xanthan gum, carrageenan, and processed starch, in addition to a culture solution such as skim milk powder and a whey degradation product.

In the present invention, examples of the milk include animal milk such as cow milk and processed products thereof (for example, skim milk, whole milk powder, skim milk powder, spinach milk, casein, whey, fresh cream, compound cream, butter, butter Milk powder, cheese, etc.) and vegetable milk such as soybean milk derived from soybeans. The milk may be sterilized or may not be sterilized.

According to one aspect of the present invention, what is called a fermented milk raw material mix can be used as a raw material for fermented milk (yogurt). The fermented milk raw material mix is a mixture containing raw milk and other components. This fermented milk raw material mix includes raw materials commonly used in the production of fermented milk such as raw milk, water, and other optional components (eg, sugar, sugar, sweetener, sour agent, mineral, vitamin, flavor, etc.). It is obtained by warming to dissolve and mixing. Raw milk may contain water, raw milk, pasteurized milk, skim milk, whole milk powder, skim milk powder, whole fat concentrated milk, skim concentrated milk, butter milk, butter, cream, cheese, and the like. The raw milk may contain whey protein concentrate (WPC), whey protein isolate (WPI), α-lactalbumin (α-La), β-lactoglobulin (β-Lg) and the like. .

In the present invention, fermented milk (yogurt) may be prepared by a method commonly used in the art. That is, fermented milk (yogurt) is manufactured through processes such as a raw material mix preparation process, a raw material mix (heating) sterilization process, a raw material mix cooling process, a starter addition process, a fermentation process, and a fermented milk cooling process. It's okay. Moreover, you may employ | adopt suitably the normal conditions used when manufacturing fermented milk (yogurt) in these processes. Moreover, it is preferable that the raw material mix (heating) sterilization step, the raw material mix cooling step, the starter addition step, the fermentation step, and the fermented milk cooling step are performed in this order.

In the present invention, as a medium for culturing lactic acid bacteria, a medium usually used in the art for culturing lactic acid bacteria can be used. That is, any medium can be used as long as it contains a nitrogen source, an inorganic substance and other nutrients in addition to the main carbon source. As the carbon source, lactose, glucose, sucrose, fructose, starch hydrolysate, molasses, etc. can be used depending on the assimilation ability of the bacteria used. As the nitrogen source, organic nitrogen-containing substances such as casein hydrolyzate, whey protein hydrolyzate, α-lactalbumin, β-lactoglobulin, glycomacropeptide, soybean protein hydrolyzate and the like can be used. In addition, meat extract, fish extract, yeast extract and the like can be used as the growth promoter.

In the present invention, lactic acid bacteria may be cultured in an anaerobic state, or may be cultured in a microaerobic state used in liquid stationary culture or the like. As a culture method under anaerobic conditions, for example, a known method such as a method of culturing in a carbon gas gas phase can be adopted, but other methods may be adopted. In general, the culture temperature is preferably in the range of 30 ° C. to 47 ° C., more preferably in the range of 35 ° C. to 46 ° C., and still more preferably in the range of 37 ° C. to 45 ° C. . The pH of the medium during the cultivation of lactic acid bacteria is preferably maintained within the range of 6 or more and 7 or less, but may be other pH ranges as long as the pH allows the bacteria to grow. The culture time for lactic acid bacteria and the like is usually preferably in the range of 1 hour to 48 hours, more preferably in the range of 1.5 hours to 36 hours, and more preferably in the range of 2 hours to 24 hours. More preferably it is.

According to one embodiment of the present invention, the fermented milk (yogurt) typically has a solid content of non-fat milk of 8% by weight or more, and the number of lactic acid bacteria or yeast is 10 ⁶ / ml or more and 10 ¹¹ / Ml or less.

Composition, Form, and Optional Components of Phytochemical Absorption Accelerator In the present invention, “absorption enhancer” is used in the form of lactic acid bacteria fermentation product, lactic acid bacteria culture, lactic acid bacteria metabolite, etc. as “lactic acid bacteria product”. However, it is preferably used after being formulated. Therefore, in the present invention, the “absorption enhancer” includes, for example, pharmaceuticals, as well as those provided in the form of preparations that are ingested as they are, preferably taken orally, so-called supplements, and as food additives. Also included are those that are added to other foods and foods and used to add a phytochemical absorption promoting action to the foods and foods.

Moreover, according to this invention, the food / beverage products which comprise the phytochemical absorption promoter by this invention, the processed food / beverage products, and the food / beverage product composition are also included by this invention.

In the present invention, a preparation is a preparation prepared in accordance with a conventional method, preferably an oral preparation, in combination with additives that are acceptable for formulation. This preparation may take the form of solid preparations such as tablets, powders, fine granules, granules, capsules, pills, sustained-release preparations, and liquid preparations such as solutions, suspensions and emulsions. Additives that are acceptable for formulation include, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, colorants, fragrances, buffers, antioxidants, pH Examples thereof include regulators. Specific examples of food additives include seasonings such as processed seasonings, flavor seasonings, and cooking mixes.

In the present invention, the food and drink and the food and drink composition are processed for human and animal food and drink, and are orally used as solutions, suspensions, emulsions, powders, solid molded articles, and the like. There is no particular limitation as long as it is an ingestible form. Specific examples of foods and drinks and food and drink compositions include milk products (including processed milk), yogurts, lactic acid bacteria beverages, fermented milk, ice creams, creams, cheeses, and other dairy products; Beverages, fruit juice drinks, vegetable drinks, soy milk drinks, coffee drinks, tea drinks, jelly drinks, nutrition drinks, cosmetic drinks, powdered drinks such as cocoa and smoothies, sports powder drinks, nutrition-enriched powder drinks, cosmetic powders Beverages such as food, powdered soup, steamed bread, concentrated beverages, alcoholic beverages; flour products such as bread, pasta, noodles, cake mix, fried flour, bread crumbs; chocolate, gum, candy, cookies, gummi, Confectionery such as snacks, Japanese confectionery, jelly, pudding dessert confectionery; curry, pasta sauce, potov, stew, Japanese-style food retort food; -Fats and oils such as margarine, spread and mayonnaise; Instant foods such as freeze-dried foods; Agricultural processed products such as canned agricultural products, jam marmalades, pickles, boiled beans, cereals, miscellaneous foods; processed fishery products; processed livestock products; Frozen foods such as pizza, doria, gratin, sugar beet, and fries; liquid foods, semi-liquid foods, and animal feeds, tablets, and cosmetics used in the oral cavity.

In the present invention, the food and drink and the food and drink composition include functional food, health nutrition food, health food, food for specified health use, functional indication food, nutrition functional food, food for the sick, infant formula, pregnant woman Or the thing of classification | category like the powdered milk for nursing women or the food-drinks with the disease risk reduction label | marker is included. Here, the indication of disease risk reduction is the indication of food or drink that may reduce the disease risk, and is based on the standard established by the FAO / WHO Joint Food Standards Committee (Codex Committee) or Refers to the standard and is a prescribed or recognized indication.

In the present invention, arbitrary components can be added to the food and drink and the food and drink composition as necessary. Such optional ingredients are not particularly limited, but are usually sweeteners, acidulants, vegetables, fruits and seed juices and extracts, vitamins, minerals, amino acids, etc. Nutrients, lactic acid bacteria (excluding essential lactic acid bacteria according to embodiments of the present invention), useful microorganisms such as bifidobacteria and propionic acid bacteria, fermented products thereof, functional sugars such as oligosaccharides, royal jelly, glucosamine , Existing functional materials such as astaxanthin, collagen, polyphenol, fragrance, pH adjuster, excipient, acidulant, colorant, emulsifier, preservative and the like.

Further, as is clear from the above, according to one aspect of the present invention, there is provided use of a lactic acid bacteria product containing a polysaccharide for the production of the poorly water-soluble phytochemical absorption enhancer according to the present invention described above. Is done.

Ingestion Method of Phytochemical Absorption Accelerator In the present invention, the intake amount of the phytochemical absorption enhancer may be appropriately determined. According to one aspect of the present invention, the intake amount of the polysaccharide is 200 μg or more / day. The amount is preferably in the range of 200 μg / day to 60000 μg / day, more preferably in the range of 300 μg / day to 45000 μg / day, and more preferably in the range of 400 μg / day to 30000 μg / day. Is more preferably in the range of 500 μg / day or more and 15000 μg / day or less (in addition, the expression “mass / day or more” is synonymous with the expression “mass / day / day” or more). Yes, the expression “mass / day or less” is synonymous with the expression “mass / day / day”.) The period of ingestion is not particularly limited, but it is preferable to ingest at least once, for example.

According to another aspect of the present invention, the required dose can be converted from the required dose in animal experiments (eg, mouse experiments) to the required dose to the human body using the following formula based on Food Safety Commission data. .
(Necessary administration dose to human body (converted value)) = (Necessary administration dose to animal) × (Lower female body weight: 40 kg) ÷ (Safety factor: 100)

As is clear from the above, according to one aspect of the present invention, poorly water-soluble in the human or animal body, comprising administering or ingesting a lactic acid bacteria product containing a polysaccharide to a human or animal. A method for promoting uptake of sex phytochemicals is provided. According to another aspect of the present invention, there is provided use of a lactic acid bacteria product containing a polysaccharide to promote uptake of a poorly water-soluble phytochemical into the human or animal body.

In the following examples, the following measurement methods were applied in common.
Measurement of polysaccharide content in yogurt The content of polysaccharide in yogurt was measured according to the phenol-sulfuric acid method (Hodge et al., “Methods in carbhydrate chemistry”, Vol. 1, page 338 (1962)). Specifically, it is as follows.

First, 1 g of trichloroacetic acid was added to 10 g of yogurt and stirred well. Next, the trichloroacetic acid-added yogurt was centrifuged at 10000 rpm for 10 minutes at 4 ° C., and then the supernatant was transferred to another tube. Next, 2 volumes of 99.5% ethanol was added to the supernatant, and the ethanol-added supernatant was left overnight in a freezer. As a result, a precipitate was formed in the tube. This precipitate was centrifuged at 10,000 rpm for 10 minutes at 4 ° C., and 3 mL of ultrapure water was added to the resulting precipitate to obtain a polysaccharide extract. Then, 500 μL of a phenol reagent (5% (w / v)) is added to 500 μL of the polysaccharide extract and the mixture is stirred. Then, 2.5 mL of concentrated sulfuric acid is added to the mixture and the mixture is mixed. Was immediately stirred for 10 seconds. Thereafter, the mixture was allowed to stand at room temperature for 20 minutes or more, and the absorbance at 490 nm of the mixture was measured with a spectrophotometer. A control solution was prepared as follows, and its absorbance at 490 nm was measured in the same manner as described above. After 500 μL of a phenol reagent (5% (w / v)) was added to 500 μL of a standard glucose solution and the mixture was stirred, 2.5 mL of concentrated sulfuric acid was further added to the mixture, and the mixture was immediately added. Stir for 2 seconds. Thereafter, the mixture was left at room temperature for 20 minutes or more.

Experimental Example 1: Promotion of absorption of quercetin (Part 1)
(1) Preparation of yogurt A medium containing 10% by mass of skim milk powder was inoculated with Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078 at 43 ° C. Fermented for hours and heated. The yogurt thus obtained contained 110 μg / g of polysaccharide.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, quercetin (manufactured by Wako Pure Chemical Industries, Ltd.), quercetin and yogurt were administered to each group of rats. Here, quercetin was administered at 50 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, a group of rats administered with quercetin (control) will be referred to as “quercetin group”, and a group of rats administered with quercetin and yogurt (Example) will be referred to as “quercetin + yogurt group”.

(3) Measurement of quercetin metabolite The quercetin metabolite quercetin conjugate and isorhamnetin conjugate were measured as follows. Glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) is dissolved in 45 μL (10000 U / mL, Sigma-Aldrich) and 0.1 M sodium acetate buffer (pH 5.0) in 50 μL of serum. 5 μL of 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 μL of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 μL of a 50% acetonitrile solution containing 0.1% formic acid.

(4) Analytical conditions for HPLC / MS / MS Nexera XR (manufactured by Shimadzu Corporation) was used for HPLC, and 4500QTRAP (manufactured by Sciex) was used for the MS / MS detector. The column used was ACQUITY UPLC HSS T3 1.8 μm (2.1 × 50 mm) (manufactured by Waters), and the column temperature was set to 40 ° C. As the mobile phase, a 0.1% formic acid solution as solution A and a 0.1% formic acid-containing acetonitrile solution as solution B were prepared. The solution was kept at 30% for 1 minute, and then gradientd to 45% for 4.5 minutes to elute the desired substance. Thereafter, the column was washed with 99% B solution for 2 minutes and held with 30% B solution for 3 minutes. The flow rate was set at 0.3 mL / min. MS / MS analysis was performed in ESI negative mode. The MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of −4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.

(5) Results The results were as shown in Table 1 and FIGS. FIG. 1 is a graph showing the serum concentration of quercetin conjugate, and FIG. 2 is a graph showing the serum concentration of isorhamnetin conjugate. At any time point, the serum concentrations of the quercetin conjugate and the isorhamnetin conjugate were significantly increased in the quercetin + yogurt group as compared to the quercetin group. In addition, the area under the blood concentration-time curve (AUC) was significantly increased in the quercetin + yogurt group as compared to the quercetin group. This result means that ingestion of yogurt promotes absorption of quercetin. In the figure, the symbol “*” indicates that there is a significant difference with respect to the quercetin group at P <0.05.

Experimental Example 2: Enhancement of absorption of quercetin (Part 2)
(1) Used skim milk powder and yoghurt The culture medium used in Experimental Example 1 (1) as skim milk powder was used, and the yoghurt prepared in Experimental Example 1 was used as yoghurt.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, quercetin and nonfat dry milk, quercetin and yogurt were administered to each group of rats. Here, quercetin was administered at 50 mg / kg body weight, and skim milk powder and yogurt were administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, the group of rats administered with quercetin and skim milk powder (control) will be referred to as “quercetin + fat dry milk group”, and the group of rats administered with quercetin and yogurt (Example) will be referred to as “quercetin + yoghurt group”.

(3) Quercetin Metabolite Measurement and HPLC / MS / MS Analysis Conditions A quercetin metabolite quercetin conjugate and isorhamnetin conjugate were performed according to the method and conditions described in Experimental Example 1.

(4) Results The results were as shown in Table 2 and FIGS. FIG. 3 is a graph showing the serum concentration of quercetin conjugate, and FIG. 4 is a graph showing the serum concentration of isorhamnetin conjugate. In the quercetin + yoghurt group, the serum concentration of the quercetin metabolite at 60 minutes and 120 minutes after administration, and the isorhamnetin conjugate at 60 minutes, 120 minutes, and 240 minutes after administration were significantly increased in the quercetin + skim milk group. At all other time points, serum concentrations of quercetin metabolites or isorhamnetin conjugates increased. In addition, the area under the blood concentration-time curve (AUC) of the quercetin conjugate was significantly increased in the quercetin + yogurt group as compared to the quercetin + fat dry milk group. This result means that fermentation by lactic acid bacteria promotes absorption of quercetin. In the figure, the symbol “*” indicates that there is a significant difference with respect to the quercetin + fat dry milk group at P <0.05.

Experimental Example 3: Promotion of absorption of quercetin (part 3)
(1) Preparation of polysaccharide concentrate derived from yogurt A part of yogurt was collected, and 3 times the amount of ethanol was added to the supernatant and stored frozen. Thereafter, the supernatant was centrifuged, and a precipitate was obtained. The precipitate was freeze-dried to obtain a polysaccharide concentrate. In addition, 70 mg of polysaccharide concentrate was contained in 11.3 g of yogurt.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After 16 hours of fasting, each group of rats was administered quercetin, quercetin and polysaccharide concentrate, respectively. Here, quercetin was administered at 50 mg / kg body weight, and the polysaccharide concentrate was administered at 70 mg / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, the group of rats administered with quercetin (control) is referred to as “quercetin group”, and the group of rats administered with quercetin polysaccharide concentrate (Example) is referred to as “quercetin + polysaccharide concentrate group”.

(3) Quercetin Metabolite Measurement and HPLC / MS / MS Analysis Conditions The quercetin metabolite quercetin conjugate and isorhamnetin conjugate were measured and analyzed according to the method and conditions described in Experimental Example 1.

(4) Results The results were as shown in Table 3 and FIGS. FIG. 5 is a graph showing the serum concentration of quercetin conjugate, and FIG. 6 is a graph showing the serum concentration of isorhamnetin conjugate. Compared with the quercetin group, in the quercetin + polysaccharide concentrate group, the serum concentration of the quercetin conjugate was 480 minutes after administration, and the serum concentration of the isorhamnetin conjugate was 240 minutes and 480 minutes after administration. At all other time points, serum concentrations of quercetin metabolites or isorhamnetin conjugates increased. In addition, the area under the blood concentration-time curve (AUC) of the isorhamnetin conjugate was significantly increased in the quercetin + polysaccharide concentrate group compared to the quercetin group. This result means that intake of a lactic acid bacteria product containing a polysaccharide promotes absorption of quercetin. In the figure, the symbol “*” indicates that there is a significant difference with respect to the quercetin group at P <0.05.

Experimental Example 4: Enhanced absorption of genistein (1) Yogurt used The yogurt prepared in Experimental Example 1 was used.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, genistein (manufactured by Tokyo Chemical Industry Co., Ltd.), genistein and yogurt were administered to each group of rats. Genistein was administered at 50 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, for convenience of explanation, a group of rats administered with genistein (control) will be referred to as a “genistein group”, and a group of rats administered with genistein and yogurt (Example) will be referred to as a “genistein + yogurt group”.

(3) Measurement of genistein metabolite The genistein conjugate which is a genistein metabolite was measured as follows. That is, a glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) in 45 μL of serum was added to 45 μL (10000 U / mL, manufactured by Sigma-Aldrich), and 0.1 M sodium acetate buffer (pH 5.0). 5 μL of the dissolved 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 μL of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 μL of a 50% acetonitrile solution containing 0.1% formic acid.

(4) Analytical conditions for HPLC / MS / MS Nexera XR (manufactured by Shimadzu Corporation) was used for HPLC, and 4500QTRAP (manufactured by Sciex) was used for the MS / MS detector. The column used was ACQUITY UPLC HSS T3 1.8 μm (2.1 × 50 mm) (manufactured by Waters), and the column temperature was set to 40 ° C. As the mobile phase, a 0.1% formic acid solution as solution A and a 0.1% formic acid-containing acetonitrile solution as solution B were prepared. The solution was kept at 30% for 1 minute, and then gradientd to 45% for 4.5 minutes to elute the desired substance. Thereafter, the column was washed with 99% B solution for 2 minutes and held with 30% B solution for 3 minutes. The flow rate was set at 0.3 mL / min. MS / MS analysis was performed in ESI negative mode. The MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of −4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.

(5) Results The results were as shown in Table 4 and FIG. At 60 minutes and 480 minutes after administration, the serum concentration of genistein conjugate was significantly increased in the genistein + yogurt group as compared to the genistein group. At all other time points, serum concentrations of genistein conjugates increased. In addition, the area under the blood concentration-time curve (AUC) was significantly increased in the genistein + yogurt group as compared to the genistein group. This result means that intake of yogurt promotes genistein absorption. In the figure, the symbol “*” indicates that there is a significant difference with respect to the genistein group at P <0.05.

Experimental Example 5: Absorption promotion of epicatechin (part 1)
(1) Yogurt used The yogurt prepared in Experimental Example 1 was used.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, epicatechin, epicatechin (manufactured by Sigma-Aldrich) and yogurt were administered to each group of rats. Epicatechin was administered at 50 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, for convenience of explanation, a group of rats administered with epicatechin (control) is referred to as an “epicatechin group”, and a group of rats administered with epicatechin and yogurt (Example) is referred to as an “epicatechin + yogurt group”. To do.

(3) Measurement of epicatechin metabolite The epicatechin conjugate which is an epicatechin metabolite was measured as follows. That is, a glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) in 45 μL of serum was added to 45 μL (10000 U / mL, manufactured by Sigma-Aldrich), and 0.1 M sodium acetate buffer (pH 5.0). 5 μL of the dissolved 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 μL of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 μL of a 50% methanol solution containing 0.1% formic acid.

(4) Analytical conditions for HPLC / MS / MS Nexera XR (manufactured by Shimadzu Corporation) was used for HPLC, and 4500QTRAP (manufactured by Sciex) was used for the MS / MS detector. The column used was ACQUITY UPLC HSS T3 1.8 μm (2.1 × 50 mm) (manufactured by Waters), and the column temperature was set to 40 ° C. As the mobile phase, 0.1% formic acid solution was prepared as solution A, and 0.1% formic acid-containing methanol solution was prepared as solution B. The solution was kept at 10% for 1 minute and then gradientd to 40% for 9 minutes to elute the desired substance. Thereafter, the column was washed with 99% B solution for 2 minutes and held with 10% B solution for 3 minutes. The flow rate was set at 0.3 mL / min. MS / MS analysis was performed in ESI negative mode. The MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of −4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.

(5) Results The results were as shown in Table 5 and FIG. At 60 minutes, 120 minutes and 240 minutes after administration, the serum concentration of epicatechin conjugate was significantly increased in the epicatechin + yogurt group as compared to the epicatechin group. In addition, the area under the blood concentration-time curve (AUC) was significantly increased in the epicatechin + yogurt group as compared to the epicatechin group. This result means that ingestion of yogurt promotes epicatechin absorption. In the figure, the symbol “*” indicates that there is a significant difference with respect to the epicatechin group at P <0.05.

Experimental Example 6: Promotion of β-carotene absorption (Part 1)
(1) Yogurt used The yogurt prepared in Experimental Example 1 was used.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, rats in each group were administered β-carotene, β-carotene (manufactured by San-Ei Gen FFI Co., Ltd.) and yogurt, respectively. Β-carotene was administered at 5 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, for convenience of explanation, a group of rats administered with β-carotene (control) is referred to as “β-carotene group”, and a group of rats administered with β-carotene and yogurt (Example) is referred to as “β-carotene + yogurt group”. To do.

(3) Measurement of β-carotene 90 μL of physiological saline was added to 50 μL of serum, and 300 μL of dichloromethane methanol solution (dichloromethane: methanol = 1: 2) was added. Further, 150 μL of hexane was added to extract β-carotene. The upper layer was transferred to another tube and the solvent was removed by nitrogen reflux. A sample for HPLC was prepared by dissolving in 150 μL of 30% ethyl acetate 70% methanol solution containing 0.1% ammonium acetate.

(4) Analytical conditions for HPLC 1200 series (manufactured by Agilent Technologies) was used for HPLC. The column used was TSKgel ODS-80TsQA (5.0 × 250 mm) (manufactured by Tosoh Corporation), and the column temperature was set to 40 ° C. As the mobile phase, a 30% ethyl acetate 70% methanol solution containing 0.1% ammonium acetate was prepared. The flow rate was set at 0.3 mL / min, and the absorption wavelength at 450 nm was measured.

(5) Results The results were as shown in Table 6 and FIG. At any time point, the serum concentration of β-carotene was significantly increased in the β-carotene + yogurt group as compared to the β-carotene group. In addition, the area under the blood concentration-time curve (AUC) was significantly increased in the β-carotene + yogurt group as compared to the β-carotene group. This result means that ingestion of yogurt promotes the absorption of β-carotene. In the figure, the symbol “*” indicates that there is a significant difference from the β-carotene group at P <0.05.

Experimental Example 7: Promotion of β-carotene absorption (Part 2)
(1) Used skim milk powder and yoghurt The culture medium used in Experimental Example 1 (1) as skim milk powder was used, and the yoghurt prepared in Experimental Example 1 was used as yoghurt.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, each group of rats was administered β-carotene and skim milk powder, and β-carotene and yogurt, respectively. Β carotene was administered at 5 mg / kg body weight, and skim milk powder and yogurt were administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, for convenience of explanation, a group of rats administered with β-carotene and nonfat dry milk (control) is referred to as “β-carotene + fat dry milk group”, and a group of rats administered with β-carotene and yogurt (Example) is designated as “β-carotene + It will be called "yogurt group".

(3) Measurement of β-carotene and HPLC analysis conditions The conditions and conditions described in Experimental Example 6 were used.

(4) Results The results were as shown in Table 7 and FIG. At 60 minutes after administration, the serum concentration of β-carotene increased significantly in the β-carotene + yogurt group compared to the β-carotene + fat dry milk group. At all other time points, serum levels of β-carotene increased. In addition, the area under the blood concentration-time curve (AUC) increased in the β-carotene + yogurt group compared to the β-carotene + fat dry milk group. This result means that fermentation by lactic acid bacteria increases the absorption rate of β-carotene. In the figure, the symbol “*” indicates that there is a significant difference from the β-carotene group at P <0.05.

Experimental Example 8: Promotion of β-carotene absorption (Part 3)
(1) Polysaccharide concentrate used The polysaccharide concentrate prepared in Experimental Example 3 was used.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After 16 hours of fasting, each group of rats was administered β-carotene, β-carotene and polysaccharide concentrate, respectively. Β-carotene was administered at 5 mg / kg body weight, and polysaccharide concentrate was administered at 70 mg / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, for convenience of explanation, a group of rats administered with β-carotene (control) is referred to as “β-carotene group”, and a group of rats administered with β-carotene and a polysaccharide concentrate (Example) is designated as “β-carotene + polysaccharide concentrate”. It will be called a “group of things”.

(3) Measurement of β-carotene and HPLC analysis conditions The conditions and conditions described in Experimental Example 6 were used.

(4) Results The results were as shown in Table 8 and FIG. At 60 minutes and 120 minutes after administration, the serum concentration of β-carotene increased significantly in the β-carotene + polysaccharide concentrate group compared to the β-carotene group. At all other time points, serum levels of β-carotene increased. In addition, the area under the blood concentration-time curve (AUC) was significantly increased in the β-carotene + polysaccharide concentrate group compared to the β-carotene group. This result means that the intake of lactic acid bacteria products containing polysaccharides promotes the absorption of β-carotene. In the figure, the symbol “*” indicates that there is a significant difference from the β-carotene group at P <0.05.

Experimental example 9: absorption enhancement of lycopene (part 1)
(1) Yogurt used The yogurt prepared in Experimental Example 1 was used.
(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, lycopene (manufactured by Wako Pure Chemical Industries, Ltd.), lycopene and yogurt were administered to each group of rats. Here, lycopene was administered at 5 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the abdominal vena cava 120 minutes after administration to obtain serum. Hereinafter, a group of rats administered with lycopene (control) is referred to as a “lycopene group”, and a group of rats administered with lycopene and yogurt (Example) is referred to as a “lycopene + yogurt group”.

(3) Measurement of lycopene 500 μL of ethanol was added to 500 μL of serum. Furthermore, 2500 μL of hexane was added to extract lycopene. The upper layer was transferred to another tube and the solvent was removed by nitrogen reflux. A sample for HPLC was prepared by dissolving in 200 μL of 30% ethyl acetate 70% methanol solution containing 0.1% ammonium acetate.

(4) Analytical conditions for HPLC 1200 series (manufactured by Agilent Technologies) was used for HPLC. The column used was TSKgel ODS-80TsQA (5.0 × 250 mm) (manufactured by Tosoh Corporation), and the column temperature was set to 40 ° C. As the mobile phase, a 30% ethyl acetate 70% methanol solution containing 0.1% ammonium acetate was prepared. The flow rate was set at 0.3 mL / min, and the absorption wavelength at 470 nm was measured.

(5) Results The results were as shown in Table 9. The serum concentration of lycopene 120 minutes after administration was significantly increased in the lycopene + yogurt group as compared to the lycopene group. This result means that ingestion of yogurt promotes lycopene absorption.

Comparative Example: Promotion of Absorption of α-Glucosylrutin (1) Yogurt Used The yogurt prepared in Experimental Example 1 was used.
(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, α-glucosyl rutin (manufactured by Wako Pure Chemical Industries, Ltd.), α-glucosyl rutin and yogurt were administered to each group of rats. Here, α-glucosyl rutin was administered at 27 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, the rat group (control) administered with α-glucosyl rutin is referred to as “αG rutin group”, and the rat group (Example) administered with α-glucosyl rutin and yogurt is referred to as “α G rutin + yogurt group”.

(3) Quercetin Metabolite Measurement and HPLC / MS / MS Analysis Conditions The quercetin metabolite quercetin conjugate concentration and isorhamnetin conjugate concentration were measured according to the method and conditions described in Experimental Example 1.

(4) Results The results were as shown in Table 10 and FIGS. FIG. 12 is a graph showing the serum concentration of quercetin conjugate, and FIG. 13 is a graph showing the serum concentration of isorhamnetin conjugate. There was no difference in the serum concentration of the quercetin conjugate and the serum concentration of the isorhamnetin conjugate between the αG rutin group and the αG rutin + yogurt group. Further, the area under the blood concentration-time curve (AUC) of the quercetin conjugate and the isorhamnetin conjugate did not differ between the αG rutin group and the αG rutin + yogurt group.

Experimental example 10: Solubility of phytochemical (1) Experimental method Epicatechin (manufactured by Sigma Aldrich), catechin (manufactured by Tokyo Chemical Industry Co., Ltd.), quercetin (manufactured by Wako Pure Chemical Industries, Ltd.), genistein (Tokyo Chemical Industry Co., Ltd.) Company), rutin (manufactured by Wako Pure Chemical Industries, Ltd.), α-glucosyl rutin (manufactured by Wako Pure Chemical Industries, Ltd.), hesperidin (manufactured by Wako Pure Chemical Industries, Ltd.), naringin (manufactured by Sigma Aldrich), naringenin (Sigma) Aldrich), kaempferol (Extra Synthase), β-carotene (Wako Pure Chemical Industries), and lycopene (Wako Pure Chemical Industries) were used. According to the administration dose used in the experimental examples, epicatechin, catechin, quercetin, genistein, naringenin, kaempferol, and luteolin were each added to 33.3 mg with 10 mL of ultrapure water. The phytochemical of the glycoside is 67.3 mg (33.3 mg as quercetin) of rutin, so that the amount of aglycon (part other than the carbohydrate obtained by hydrolyzing the glycoside) is 33.3 mg, α-glucosyl 10 mL of ultrapure water was added to 89.6 mg of rutin (33.3 mg as quercetin), 67.3 mg of hesperidin (33.3 mg as hesperetin), 71.0 mg of naringin (33.3 mg as naringenin). According to the administration dose used in the experimental examples, the terpenoid was added with β-carotene and lycopene to 3.3 mg each and 10 mL of ultrapure water. The prepared solution was shaken for 3 hours and then centrifuged at 2000 × g for 10 minutes. The centrifugal supernatant was filtered using a 0.45 μL filter. Absorbance of the centrifugal supernatant (epicatechin, catechin, hesperidin, naringin, naringenin is 280 nm, genistein is 260 nm, quercetin, rutin, α-glucosylrutin, kaempferol is 360 nm, β-carotene is 450 nm, lycopene is 470 nm, spectrophotometer Was measured. Each compound was dissolved in 80% methanol or methanol, a calibration curve was prepared, and the concentration of the centrifugal supernatant was determined. The series of operations described above was performed under a temperature condition of 21 ± 2 ° C. And the dissolution rate was computed according to the following formula | equation.
Dissolution rate (%) = ((concentration of centrifugal supernatant after shaking dissolution (w / v) ÷ (concentration of solution before shaking dissolution (w / v))) × 100

(2) Results The results were as shown in Table 11 and Table 12. Catechin and α-glucosyl rutin were water-soluble phytochemicals with a dissolution rate of 89% or more. On the other hand, epicatechin, genistein, quercetin, rutin, kaempferol, hesperidin, naringin, naringenin, β-carotene, lycopene, and luteolin had a solubility of 88% or less and were poorly water-soluble. These results mean that in the poorly water-soluble phytochemical having a dissolution rate of 88% or less, intake of a lactic acid bacteria product containing a polysaccharide promotes absorption of the phytochemical. Further, “(concentration (w / v) of the centrifugal supernatant after dissolution by shaking)” obtained for the dissolution rate measurement is called “saturated solubility” and is described in Table 11 and Table 12 together. In addition, the phytochemical of glycoside was described as an aglycon conversion value.

Experimental Example 11: Promotion of Luteolin Absorption (1) Yogurt Used The yogurt prepared in Experimental Example 1 was used.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, each group of rats was administered luteolin (manufactured by Tokyo Chemical Industry Co., Ltd.), luteolin and yogurt. Luteolin was administered at 50 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, for convenience of explanation, a group of rats administered with luteolin (control) will be referred to as “luteoline group”, and a group of rats administered with luteolin and yogurt (Example) will be referred to as “luteoline + yogurt group”.

(3) Measurement of luteolin metabolite The luteolin conjugate which is a luteolin metabolite was measured as follows. That is, a glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) in 45 μL of serum was added to 45 μL (10000 U / mL, manufactured by Sigma-Aldrich), and 0.1 M sodium acetate buffer (pH 5.0). 5 μL of the dissolved 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 μL of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 μL of a 50% acetonitrile solution containing 0.1% formic acid.

(4) Analytical conditions for HPLC / MS / MS Nexera XR (manufactured by Shimadzu Corporation) was used for HPLC, and 4500QTRAP (manufactured by Sciex) was used for the MS / MS detector. The column used was ACQUITY UPLC HSS T3 1.8 μm (2.1 × 50 mm) (manufactured by Waters), and the column temperature was set to 40 ° C. As the mobile phase, a 0.1% formic acid solution as solution A and a 0.1% formic acid-containing acetonitrile solution as solution B were prepared. The solution was kept at 30% for 1 minute, and then gradientd to 45% for 4.5 minutes to elute the desired substance. Thereafter, the column was washed with 99% B solution for 2 minutes and held with 30% B solution for 3 minutes. The flow rate was set at 0.3 mL / min. MS / MS analysis was performed in ESI negative mode. The MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of −4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.

(5) Results The results were as shown in Table 13 and FIG. At 60 minutes, 120, and 240 minutes after administration, the serum concentration of the luteolin conjugate was significantly increased in the luteolin + yogurt group as compared to the luteolin group. At all other time points, serum concentrations of luteolin conjugates increased. In addition, the area under the blood concentration-time curve (AUC) was significantly increased in the luteolin + yogurt group as compared to the luteolin group. This result means that intake of yogurt promotes absorption of luteolin. In the figure, the symbol “*” indicates that there is a significant difference with respect to the luteolin group at P <0.05.

Experimental example 12: Promotion of absorption of naringenin (1) Yogurt used The yogurt prepared in Experimental example 1 was used.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, rats of each group were administered with naringenin (manufactured by Tokyo Chemical Industry Co., Ltd.), naringenin and yogurt, respectively. Naringenin was administered at 50 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. Hereinafter, for convenience of explanation, a group of rats administered with naringenin (control) will be referred to as “naringenin group”, and a group of rats administered with naringenin and yogurt (Example) will be referred to as “naringenin + yogurt group”.

(3) Measurement of Naringenin Metabolite Naringenin conjugate which is a naringenin metabolite was measured as follows. That is, a glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) in 45 μL of serum was added to 45 μL (10000 U / mL, manufactured by Sigma-Aldrich), and 0.1 M sodium acetate buffer (pH 5.0). 5 μL of the dissolved 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 μL of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 μL of a 50% acetonitrile solution containing 0.1% formic acid.

(4) Analytical conditions for HPLC / MS / MS Nexera XR (manufactured by Shimadzu Corporation) was used for HPLC, and 4500QTRAP (manufactured by Sciex) was used for the MS / MS detector. The column used was ACQUITY UPLC HSS T3 1.8 μm (2.1 × 50 mm) (manufactured by Waters), and the column temperature was set to 40 ° C. As the mobile phase, a 0.1% formic acid solution as solution A and a 0.1% formic acid-containing acetonitrile solution as solution B were prepared. The solution was kept at 30% for 1 minute, and then gradientd to 45% for 4.5 minutes to elute the desired substance. Thereafter, the column was washed with 99% B solution for 2 minutes and held with 30% B solution for 3 minutes. The flow rate was set at 0.3 mL / min. MS / MS analysis was performed in ESI negative mode. The MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of −4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.

(5) Results The results were as shown in Table 14 and FIG. At 60 minutes after administration, the serum concentration of naringenin conjugate was significantly increased in the naringenin + yogurt group compared to the naringenin group. At all other time points, serum concentrations of naringenin conjugates increased. In addition, the area under the blood concentration-time curve (AUC) was significantly increased in the naringenin + yogurt group as compared to the naringenin group. This result means that ingestion of yogurt promotes absorption of naringenin. In the figure, the symbol “*” indicates that there is a significant difference with respect to the naringenin group at P <0.05.

Experimental Example 13: Promotion of absorption of lycopene (part 2)
(1) Yogurt used The yogurt prepared in Experimental Example 1 was used.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, lycopene (manufactured by Rico Red), lycopene and yogurt were administered to each group of rats. Here, lycopene was administered at 5 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. The serum concentration of lycopene was measured according to the method and conditions described in Experimental Example 9. Hereinafter, a group of rats administered with lycopene (control) is referred to as a “lycopene group”, and a group of rats administered with lycopene and yogurt (Example) is referred to as a “lycopene + yogurt group”.

(3) Results The results were as shown in Table 15 and FIG. At 60 minutes, 120 minutes, and 240 minutes after administration, the serum concentration of lycopene was significantly increased in the lycopene + yogurt group as compared to the lycopene group. In addition, the area under the blood concentration-time curve (AUC) increased in the lycopene + yogurt group compared to the lycopene group. This result means that ingestion of yogurt promotes lycopene absorption. In the figure, the symbol “*” indicates that there is a significant difference from the lycopene group at P <0.05.

Experimental Example 14: Promotion of β-carotene absorption (Part 4)
(1) Preparation of yogurt After inoculating Lactobacillus bulgaricus OLL1224 and Lactobacillus bulgaricus OLL1247 into a medium containing 10% by mass of skim milk powder and 0.5 mM sodium formate, the medium was incubated at 43 ° C. at pH 4 Fermented to 6 until heated. The yogurt thus obtained contained 88 μg / g and 68 μg / g of polysaccharides, respectively.

(2) Experimental method After acclimatizing 24 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, β-carotene, β-carotene and yogurt (Lactobacillus bulgaricus OLL1224), β-carotene and yogurt (Lactobacillus bulgaricus OLL1247) were administered to each group of rats. Here, β-carotene was administered at 5 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. The serum concentration of β-carotene was measured according to the method and conditions described in Experimental Example 6.
Hereinafter, a group of rats administered with β-carotene (control) is referred to as “β-carotene group”, and a group of rats (Example) administered with β-carotene and yogurt (Lactobacillus bulgaricus OLL1224) is referred to as “β-carotene + OLL1224 group”. A group of rats (Example) administered with β-carotene and yogurt (Lactobacillus bulgaricus OLL1247) is referred to as “β-carotene + OLL1247 group”.

(3) Results The results were as shown in Table 16. The area under the blood concentration-time curve (AUC) was significantly increased in the β-carotene + OLL1224 and β-carotene + OLL1247 groups compared to the β-carotene group. This result means that ingestion of yogurt promotes the absorption of β-carotene.

Experimental Example 15: Promotion of β-carotene absorption (Part 5)
(1) Preparation of yogurt After inoculating Streptococcus thermophilus OLS3290 and Streptococcus thermophilus OLS3078 in a medium containing 10% by weight of skim milk powder and 0.1% by weight of casein peptide (manufactured by DOMO), the medium was incubated at 43 ° C. And fermented to pH 4.6 and heated. The yogurt thus obtained contained 76.3 μg / g and 45.8 μg / g of polysaccharides, respectively.

(2) Experimental method After acclimatizing 24 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, rats of each group were administered β-carotene, β-carotene and yogurt (Streptococcus thermophilus OLS3290), β-carotene and yogurt (Streptococcus thermophilus OLS3078), respectively. Here, β-carotene was administered at 5 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. The serum concentration of β-carotene was measured according to the method and conditions described in Experimental Example 6. Hereinafter, a group of rats administered with β-carotene (control) is referred to as a “β-carotene group”, and a group of rats administered with β-carotene and yogurt (Streptococcus thermophilus OLS3290) (Examples) is designated as “β-carotene + OLS3290 group”, β A group of rats (Example) administered with carotene and yogurt (Streptococcus thermophilus OLS3078) will be referred to as “β-carotene + OLS3078 group”.

(3) Results The results were as shown in Table 17. The area under the blood concentration-time curve (AUC) was significantly increased in the β-carotene + OLS3290 group compared to the β-carotene group. This result means that ingestion of yogurt promotes the absorption of β-carotene.

Experimental Example 16: Promotion of β-carotene absorption (Part 6)
(1) Preparation of yogurt After inoculating a medium containing 10% by mass of skim milk powder with a commercially available starter (Caspian Sea Yogurt, manufactured by Fujikko Co., Ltd.), Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078 The medium was fermented and heated at 43 ° C. until pH 4.6 was reached. The yogurt thus obtained contained 15 μg / g and 54 μg / g of polysaccharide.

(2) Experimental method After acclimatizing 24 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After fasting for 16 hours, each group of rats was administered β-carotene, β-carotene and yogurt (Caspian Sea yogurt), β-carotene and yogurt (Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078). Here, β-carotene was administered at 5 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. The serum concentration of β-carotene was measured according to the method and conditions described in Experimental Example 6. Hereinafter, the group of rats administered with β-carotene (control) is referred to as “β-carotene group”, and the group of rats administered with β-carotene and yogurt (Caspian Sea yogurt) (Example) is “β-carotene + Caspian Sea YG group”. A group of rats (Example) administered with β-carotene and yogurt (Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078) will be referred to as “β-carotene + OLL1247 × OLS3078”.

(5) Results The results were as shown in Table 18. The area under the blood concentration-time curve (AUC) was significantly increased in the β-carotene + OLL1247 × OLS3078 group compared to the β-carotene group. This result means that ingestion of yogurt promotes the absorption of β-carotene.

Experimental Example 17: Promotion of absorption of quercetin (part 4)
(1) Yogurt used In a medium containing 10% by mass of skim milk powder, a commercially available starter (Lactobacillus bulgaricus 2038 and Streptococcus thermophilus 1131 bacterium isolated from Meiji Bulgaria Yogurt (Meiji Co., Ltd.)), lacto After inoculation with Bacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078, the medium was fermented at 43 ° C. until it reached pH 4.6 to prepare yogurt.

(2) Experimental method After acclimatizing 24 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After 16 hours of fasting, each group of rats was administered quercetin, quercetin and yogurt, respectively. Here, quercetin was administered at 50 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. The serum concentrations of the quercetin conjugate, which is a quercetin metabolite, and the isorhamnetin conjugate were measured according to the method and conditions described in Experimental Example 1. Hereinafter, the group of rats administered with quercetin (control) is referred to as “quercetin group”, and the group of rats administered with quercetin and yogurt (Lactobacillus bulgaricus 2038 and Streptococcus thermophilus 1131) (Example) is designated as “quercetin + LB81”. Group ”, a group of rats (Example) administered with quercetin and yogurt (Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078) will be referred to as“ Quercetin + OLL1247 × OLL3078 ”.

(3) Results The results were as shown in Table 19. The area under the blood concentration-time curve (AUC) of the quercetin conjugate was significantly increased in the quercetin + LB81 group and the quercetin + OLL1247 × OLS3078 group as compared with the quercetin group. This result means that fermentation by lactic acid bacteria promotes absorption of quercetin.

Experimental Example 18: Absorption promotion of epicatechin (part 2)
(1) Yogurt used The yogurt prepared in Experimental Example 1 was used.

(2) Experimental method After acclimatizing 16 rats (SD, male, 8 weeks old, SLC Japan) for 7 days, the rats were divided into groups of 8 rats. After 16 hours of fasting, each group of rats was administered cocoa bean extract, cocoa bean extract and yogurt, respectively. The cocoa bean extract was prepared by extracting cocoa bean powder obtained by defatting unfermented cocoa beans with 50% ethanol (v / v), and then concentrating and lyophilizing the extract. The obtained cacao bean extract contained 188 mg / g of epicatechin. The cacao bean extract was administered as epicatechin at 50 mg / kg body weight, and yogurt was administered at 11.3 g / kg body weight. Blood was collected from the tail vein before administration, 60 minutes, 120 minutes, 240 minutes, and 480 minutes after administration to obtain serum. The serum concentration of epicatechin conjugate, which is an epicatechin metabolite, was measured according to the method and conditions described in Experimental Example 5. Hereinafter, for convenience of explanation, the group of rats administered with the cocoa bean extract (control) is referred to as “cocoa bean extract group”, and the group of rats administered with the cocoa bean extract and yogurt (Example) is referred to as “cocoa bean extract”. It will be referred to as a “+ yogurt group”.

(3) Results The results were as shown in Table 20 and FIG. At 60 minutes and 120 minutes after administration, the serum concentration of epicatechin conjugate was significantly increased in the cocoa bean extract + yogurt group as compared with the cocoa bean extract group. In addition, the area under the blood concentration-time curve (AUC) was significantly increased in the cocoa bean extract + yogurt group as compared to the cocoa bean extract group. This result means that ingestion of yogurt promotes absorption of epicatechin contained in the cocoa bean extract. In the figure, the symbol “*” indicates that there is a significant difference with respect to the cacao bean extract group at P <0.05.

Claims (17)

1. A poorly water-soluble phytochemical absorption promoter comprising a lactic acid bacteria product containing a polysaccharide as an active ingredient.
2. The poorly water-soluble phytochemical absorption promoter according to claim 1, wherein the lactic acid bacteria product is produced by a combination of Lactobacillus bulgaricus and Streptococcus thermophilus.
3. The poorly water-soluble phytochemical absorption accelerator according to claim 1 or 2, wherein the poorly water-soluble phytochemical has a dissolution rate of 88% or less.
4. The poorly water-soluble phytochemical absorption accelerator according to claim 1 or 2, wherein the poorly water-soluble phytochemical has a dissolution rate of 50% or less.
5. The poorly water-soluble phytochemical absorption accelerator according to any one of claims 1 to 4, wherein the poorly water-soluble phytochemical is selected from the group consisting of polyphenols, organic sulfur compounds, and terpenoids. .
6. The poorly water-soluble phytochemical absorption promoter according to claim 5, wherein the polyphenol is a flavonoid.
7. The poorly water-soluble phytochemical absorption promotion according to claim 6, wherein the flavonoids are selected from the group consisting of flavones, isoflavones, flavonols, flavanones, flavan-3-ols, anthocyanins and their analogs. Agent.
8. The poorly water-soluble phytochemical absorption accelerator according to claim 7, wherein the flavonoid is flavone, isoflavone, flavonol, flavanone, flavan-3-ol or an analog thereof.
9. The poorly water-soluble phytochemical absorption accelerator according to claim 5, wherein the terpenoid is tetraterpene or an analog thereof.
10. The difficulty according to any one of claims 1 to 9, wherein the poorly water-soluble phytochemical is selected from quercetin, genistein, epicatechin, luteolin, naringenin, β-carotene and lycopene and analogs thereof. Water-soluble phytochemical absorption accelerator.
11. The poorly water-soluble phytochemical absorption promoter according to any one of claims 1 to 10, wherein the lactic acid bacteria product is fermented milk.
12. A food additive comprising the poorly water-soluble phytochemical absorption promoter according to any one of claims 1 to 11.
13. A food or drink or a food or drink composition comprising the poorly water-soluble phytochemical absorption promoter according to any one of claims 1 to 12.
14. A method for promoting uptake of a poorly water-soluble phytochemical into a human or animal body, which comprises administering or ingesting the lactic acid bacteria product containing the polysaccharide to the human or animal.
15. The method according to claim 14, wherein the lactic acid bacteria product containing the polysaccharide is in the form of a poorly water-soluble phytochemical absorption enhancer according to any one of claims 1 to 11.
16. Use of lactic acid bacteria products containing polysaccharides to promote uptake of poorly water-soluble phytochemicals into the human or animal body.
17. Use of a lactic acid bacterium product containing a polysaccharide for the production of a poorly water-soluble phytochemical absorption enhancer according to any one of claims 1 to 11.
    
    

Images